BEHAVIOURAL SCIENCE IN CANCER SCREENING, CONTROL AND COMMUNICATION
With
Dr Rachael Dodd
Senior Research Fellow,
The Daffodil Centre, a Cancer Council NSW & The University of Sydney Joint Venture
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney | April 2025
Dr Dodd completed her undergraduate in Psychology (2007), Masters in Health Psychology (2009) and PhD in Psychology (2016) in the UK. Her PhD focused on the psychosocial impact of HPV in people diagnosed with head and neck cancer, which resulted in the development of an education resource which is being implemented into clinical practice here in Australia and is available online. Dr Dodd relocated to The University of Sydney in Australia in 2017, following the completion of her PhD. Her research capitalised on her expertise in HPV and focused on the changes to the cervical screening program that commenced in Australia in 2017.
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
Dr Dodd has published 78 research papers and is a CI on grants worth over $20 million. This has included being the lead investigator of an International Lung Cancer Foundation Young Investigator Grant, to co-design decision support tools for lung cancer screening in Australia and she is leading a consortium to develop the suite of information materials and education resources for the upcoming National Lung Cancer Screening Program.
Source: Supplied
https://orcid.org/0000-0002-8080-6359
-
Next generation nanomedicine and radiopharmaceuticals to treat cancer
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Neuroscience, neuropharmacology and exercise science
Dr Jacob Thorstensen is an early-career Assistant Professor in Neuroscience and Physiology in the Faculty of Health Sciences & Medicine at Bond University. He is also an honorary research fellow in The School of Biomedical Sciences at The University of Queensland. His work has unveiled several new neuroscientific mechanisms which have future applications for movement disorders.
